marked.bio

KRAS G12C inhibitor (ON/OFF) · small molecule

BBO-8520

1 active trials, targeting KRAS G12C. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 1 1 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of BBO-8520.

  1. BridgeBio Oncology Therapeutics 1

Trials

1 of 1 trials shown

  1. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2031-04 NCT06343402

    BBO-8520pembrolizumabBBO-10203

    …umented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation

    KRAS G12CNon-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C